The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC).
 
Joseph W. Kim
Stock and Other Ownership Interests - ABION (I); Celgene (I); Johnson & Johnson (I)
Consulting or Advisory Role - Clovis Oncology; EMD Serono; Sanofi; Voluntis
Research Funding - Immune Design
 
Matthew I. Milowsky
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst)
Other Relationship - Asieris Pharmaceuticals (Inst)
 
Noah M. Hahn
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst)
 
David J. Kwiatkowski
Consulting or Advisory Role - Genentech/Roche; Novartis
Research Funding - AADi; Genentech/Roche; Revolution Medicines
 
Alicia K. Morgans
Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Genentech; Janssen; Janssen; Janssen Oncology; Sanofi
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences; Sanofi
Research Funding - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Genentech; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Sanofi
 
Nancy B. Davis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Taris BioMedical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Jounce Therapeutics; Taris BioMedical
 
Leonard Joseph Appleman
Consulting or Advisory Role - AADi
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Amgen; Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)
Other Relationship - Pfizer
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Viralytics (Inst)
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Janssen
Research Funding - Aragon Pharmaceuticals (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst)
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Yu Shyr
Consulting or Advisory Role - Aduro Biotech; GlaxoSmithKline; Janssen Research & Development; Novartis; Pfizer; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Royalty for TNBCType for Insight Genetics. TNBCType is a web-based subtyping tool TNBCtype for candidate TNBC samples using our gene expression meta data and classification method.
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; ImmunoMet; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Jeffrey Sklar
Stock and Other Ownership Interests - Precipio
Research Funding - Jilin Zixin (Inst)
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi